Press & News

The next generation biopharmaceuticals

Press releases 2014

2014-11-27

Nordic Nanovector and Affibody collaborate on advanced radio-immunotherapies program for Multiple Myeloma

Oslo, Norway and Solna, Sweden – Nordic Nanovector ASA and Affibody AB today announced that the companies have entered into a three-year collaborative research agreement to discover and develop new advanced radio-immunotherapies (RIT) for multiple myeloma.[read more]

Older press releases

2014-11-20

Interim Report – January to September 2014

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report covering the Third Quarter 2014.[read more]

2014-08-22

Interim Report – January to June 2014

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its report for the second quarter 2014.[read more]

2014-05-20

Interim Report – January to March 2014

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report covering the First Quarter 2014.[read more]

Affibodys latest Press releases

2018-05-21

Affibody Presents at Anglonordic Life Science

Solna, Sweden, May 21, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug...[read more]

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

Interim Report Q2 (August 23, 2018)

Investor information